

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

COATES et al.

Examiner: F. Krass

Serial No.: 07/835,964

Group Art Unit: 1614

Filed: February 20, 1992 /

For: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

AMENDMENT UNDER 37 C.F.R. § 1.312(a)Assistant Commissioner for Parents  
Washington, DC 20231

SIR:

Further to the amendment of March 10, 2000, entry of the following amendments is respectfully requested.

IN THE CLAIMS

Please amend claims 25, 31, 32, 64-67, and 81-82 as follows:

25. A method for treating a human suffering from HIV infection comprising administering to said human [a pharmaceutical composition comprising]:  
a compound which is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof [, another agent having antiviral activity,] and a pharmaceutically acceptable carrier, [and] wherein the amount of the (+)-enantiomer of said compound or of said pharmaceutically acceptable salt present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof and  
another agent having antiviral activity.

31. A method according to claim 25, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] no more than 2% w/w.

32. A method according to claim 31, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] no more than 1% w/w